Leeds Institute of Rheumatic and Musculoskeletal Medicine and Leeds Teaching Hospitals NHS Trust, Leeds, and University of Oxford, Oxford, UK.
Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK.
Arthritis Care Res (Hoboken). 2018 Aug;70(8):1198-1205. doi: 10.1002/acr.23460. Epub 2018 Jun 28.
To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA).
Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0-30) is the total of three 0-10 scores for the Health Assessment Questionnaire disability index (recalculated from 0-3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA).
RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria.
RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.
分析 Routine Assessment of Patient Index Data 3（RAPID3），这是一个患者报告的综合指标，最初旨在为临床护理提供可行性。RAPID3 最初在类风湿关节炎中开发，但已在许多风湿性疾病中得到应用。我们分析了银屑病关节炎（PsA）患者的 RAPID3。
对 Tight Control of Psoriatic Arthritis（TICOPA）临床试验和 Long-Term Outcome in Psoriatic Arthritis Study（LOPAS II）的两个独立数据集进行了事后分析，LOPAS II 是一个观察队列。RAPID3（范围 0-30）是健康评估问卷残疾指数（从 0-3 重新计算）、疼痛视觉模拟量表（VAS）和全球 VAS 的三个 0-10 评分的总和。根据 Spearman 相关系数、标准化反应均值、SEM、最小可检测差异、最小有意义差异（在病情改善的患者中）和受试者工作特征曲线，将 RAPID3 评分与 PASDAS、DAPSA 和其他可用的临床指标进行比较。比较 RAPID3 缓解与标准最小疾病活动（MDA）和极低疾病活动（VLDA）标准的标准。
在 TICOPA 中，RAPID3 与 PASDAS 显著相关（r = 0.79，P < 0.01），与 LOPAS II 中的 DAPSA 相关（ρ = 0.59，P < 0.01），并且在两个数据集的大多数其他指标中均相关。在 TICOPA 中，RAPID3 在 48 周时在与 DAPSA 和 PASDAS 可比的水平上区分了严格控制和标准护理（P < 0.01）。在 TICOPA 中，RAPID3 缓解在 MDA 和 VLDA 标准之间的中间区分了治疗组。
RAPID3 在 PsA 中与 PASDAS 和 DAPSA 相比具有相当的信息量，并且在常规临床护理中具有更大的可行性。
